Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice
about
Enhancement of the immune response to residual intrahepatic tumor tissue by laser-induced thermotherapy (LITT) compared to hepatic resection.Cell-based vaccines for the stimulation of immunity to metastatic cancers.Activation of the immune system in cancer patients.Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancerAntibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivoTargeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation.MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.Gene therapy: development of immunostimulatory treatments for cancer.Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cellsEnhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection.Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growthDoes B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma.Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix.Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity.Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter.Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines.The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.Transfection of CD40 in a human oral squamous cell carcinoma keratinocyte line upregulates immune potency and costimulatory molecules.Enhancement of cALL immunogenicity by co-culture with a CD154 expressing 293 cell line.Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.Gene transfer of costimulatory molecules into a human colorectal cancer cell line: requirement of CD54, CD80 and class II MHC expression for enhanced immunogenicity.IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes.B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells.Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells.MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cellsTumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor.Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma.Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma.Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma.
P2860
Q33208059-C9497090-619F-4BD5-A210-00C2DF2029C0Q33776134-6A8E5AFB-91F8-40A9-BFE1-B40D93F868E2Q33803922-B6E26BC9-A0AB-4516-9F16-3AF8DB58635AQ33815011-EBEBE51D-0C1C-4EBE-9272-73B9A795E9B2Q33870240-9E2DBDC4-017B-41C2-9227-F043DAFE4FE4Q33887448-7667730B-3063-46B8-972A-224CF388F666Q33956237-4AA072F1-5504-4C40-BE42-BCC2BE890376Q34012255-67450A5F-18AB-4BD6-AEDB-E1152D21ED4CQ34161849-87364E8B-78C4-4D80-91E2-AEF25743CACDQ34187915-B03D2E32-8F85-4BDB-A094-980A8562130DQ35748591-C5857540-30EE-45D4-A371-3391B153BE5BQ35950374-13601DD5-1BE4-4019-8175-7DB97297DA55Q36021225-ED55B05F-04BA-449E-8C47-78F807FDC3B3Q36131252-5E6A28F8-8B3D-4472-A663-C97A194B23FEQ36135476-40246A6C-CCFE-4176-9A01-D3695C2CF185Q36241838-C55D5C33-9E18-4ADF-A108-35067CF0B6CBQ36322686-A64C8042-AC21-45C8-BDE1-D560F958ACEDQ36365923-8AB9E01C-A63B-4EA6-9EF6-9A4FBF2FEC95Q36386903-1067E0A8-9BCB-4391-8C85-353837D76756Q37382571-397A6212-BAD2-427C-A0B8-CDE569DBC19BQ37410596-E738EAAA-D8D3-4C87-818E-741609B29215Q37729253-058D040A-5C86-4EEC-8F2C-43BD6F06EF94Q38289283-B0922002-041F-4FEC-9575-875FD2ED9E23Q39136897-8D730731-ABFF-401F-A243-61EFC358CBEBQ39722010-E3B52D1F-A390-4AA1-8168-95493975C6D1Q39924299-FE4930CC-3102-483B-ADDF-FE34FFDC9020Q40088629-F607741B-C05E-498A-BE9F-49A02318E627Q40325737-409269D6-F9C5-46D6-A747-8D8342C84839Q40790005-1412CB7A-7D51-4C96-9214-B62B25205710Q40912686-F5589E0D-18C9-4F1F-A45D-29B22520E708Q41030846-D5C73103-7AE7-4F1C-9550-2FAD58F2938FQ41095713-DFBBE7D6-D4B2-49DA-ACC4-083F29A8D4E6Q41105180-9A7911F4-B168-426C-A037-275816E21997Q41788470-2E230547-3553-4974-8DD5-FEE5A1F154FCQ41920366-60415C00-3193-4BE9-9AAE-472F1242E70EQ42114592-911BDAF1-D693-4989-B981-510684645F59Q45861119-4B626BC1-3321-409A-BB79-3CD2373658FFQ46276232-E1043DB0-1B62-4773-931D-9CCDBBDB6B93Q53342350-40295621-0B3C-4C93-B9BA-BDB650F78D98Q53961221-585914F6-6CDD-4BAB-931E-7E2BACB614E5
P2860
Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Major histocompatibility compl ...... ejection in tumor-bearing mice
@ast
Major histocompatibility compl ...... ejection in tumor-bearing mice
@en
type
label
Major histocompatibility compl ...... ejection in tumor-bearing mice
@ast
Major histocompatibility compl ...... ejection in tumor-bearing mice
@en
prefLabel
Major histocompatibility compl ...... ejection in tumor-bearing mice
@ast
Major histocompatibility compl ...... ejection in tumor-bearing mice
@en
P2093
P2860
P356
P1476
Major histocompatibility compl ...... ejection in tumor-bearing mice
@en
P2093
L Glimcher
S Ostrand-Rosenberg
P2860
P304
P356
10.1084/JEM.181.2.619
P407
P577
1995-02-01T00:00:00Z